The relationship between a decline in the rupee and better margins for IT companies is well known. What is not discussed much is that pharma firms are also big beneficiaries when the rupee weakens. To put it in perspective: Among India's top pharma companies, there are some that have more than 57% of their sales coming from exports. In one case, export contribution is as high as 88%. So, a decline in the rupee increases the probability of their margins moving higher in the coming quarters. Another plus: It is one sector where US President-elect Donald Trump is unlikely to create problems. He cannot afford to mess with an already messed-up US healthcare system.
